Develops off-the-shelf virus-based treatment candidates for patients with cancer, including people with solid tumors.
10-K for FY2025, filed Mar 12, 2026
10-Q for Q3 FY2026, filed Nov 12, 2026
−$21.9MView ↗
Competes with AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, Merck &, Novartis, Pfizer, Genentech, Johnson & Johnson, Replimune Group, Amgen, Astellas Pharma, Istari Oncology, Orca Therapeutics, CG Oncology, ImmVira, IconOVir Bio, and FerGene
10-K for FY2025, filed Mar 12, 2026The development and commercialization of new product candidates is highly competitive. We face competition from major pharmaceutical…View ↗
Loading...